Adagene Inc. (ADAG)
1.53
0.00 (0.00%)
At close: Apr 17, 2025, 3:55 PM
1.64
7.01%
Pre-market: Apr 21, 2025, 06:12 AM EDT
0.00% (1D)
| Bid | 1.2 |
| Market Cap | 57.66M |
| Revenue (ttm) | 815.75K |
| Net Income (ttm) | -31.85M |
| EPS (ttm) | -0.74 |
| PE Ratio (ttm) | -2.07 |
| Forward PE | -1.89 |
| Analyst | Buy |
| Ask | 2 |
| Volume | 12,990 |
| Avg. Volume (20D) | 72,025 |
| Open | 1.66 |
| Previous Close | 1.53 |
| Day's Range | 1.50 - 1.66 |
| 52-Week Range | 1.32 - 3.58 |
| Beta | 0.61 |
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical tr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 138
Stock Exchange NASDAQ
Ticker Symbol ADAG
Website https://www.adagene.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADAG stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 422.88% from the latest price.
Stock Forecasts8 months ago
+8.86%
Adagene shares are trading higher after the compan...
Unlock content with
Pro Subscription
